MARKET

TARA

TARA

Protara Therapeutics Inc
NASDAQ
2.320
-0.060
-2.52%
Closed 16:10 11/17 EST
OPEN
2.380
PREV CLOSE
2.380
HIGH
2.430
LOW
2.245
VOLUME
726.12K
TURNOVER
0
52 WEEK HIGH
7.82
52 WEEK LOW
2.090
MARKET CAP
142.84M
P/E (TTM)
-1.6752
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TARA last week (1109-1113)?
Weekly Report · 2d ago
Analysts Offer Insights on Healthcare Companies: Satellos Bioscience (MSLE) and Protara Therapeutics (TARA)
TipRanks · 11/09 12:30
Protara’s Pipeline Catalysts Support a Buy Rating and $25 Price Target
TipRanks · 11/09 10:45
Weekly Report: what happened at TARA last week (1102-1106)?
Weekly Report · 11/09 10:02
Protara Therapeutics GAAP EPS of -$0.35 beats by $0.02
Seeking Alpha · 11/06 13:43
Protara Therapeutics Q3 EPS $(0.35) Beats $(0.37) Estimate
Benzinga · 11/06 13:34
*Protara Therapeutics 3Q Research and Development Expenses $16.8M >TARA
Dow Jones · 11/06 13:04
*Protara Therapeutics 3Q Loss/Shr 35c >TARA
Dow Jones · 11/06 13:00
More
About TARA
Protara Therapeutics, Inc. is a clinical-stage biotechnology company focused on advancing transformative therapies for people with cancer and rare diseases. The Company's portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin, as well as a Phase II trial in pediatric patients with LMs. TARA-002 is a first-in-class TLR2/NOD2 agonist and novel immunopotentiator derived from inactivated Streptococcus pyogenes. Additionally, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral support who are otherwise unable to meet their choline needs via oral or enteral routes.

Webull offers Protara Therapeutics Inc stock information, including NASDAQ: TARA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TARA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TARA stock methods without spending real money on the virtual paper trading platform.